The use of interferon in medicine
DOI:
https://doi.org/10.12775/JEHS.2020.10.06.024Keywords
interferon, hepatitis C, COVID19Abstract
Interferons are low-molecular weight glycoproteins. They are characterized by paracrine and autocrine activity. Their production and release occurs through various types of cells, which ultimately leads to the protection of the body against viral infections. Interferons do not have direct antiviral activity but affect cells, inducing the formation of antiviral agents and "antiviral readiness" in them. Thanks to their properties interferons have been widely used in the treatment of many diseases, among others hepatitis B, hepatitis C and multiple sclerosis. In addition, they show anti-cancer effects, even in the case of chronic myeloid leukemia. They are currently an important element in the search for a drug against SARS-CoV-2.
References
Isaacs A, Lindenmann J. Virus interference. I. The interferon. J. Interferon Res. 1987;7:429–38.
Obołończyk Ł, Siekierska-Hellmann M, Sworczak K. Powikłania leczenia interferonem alfa wirusowego zapalenia wątroby typu C ze szczególnym uwzględnieniem zaburzeń funkcji tarczycy. Postepy Hig. Med. Dosw. 2008;62:309–21.
Berkman A, Kaczorowski S, Bakalar N. Wirusowe zapalenie wątroby : typy od A do G : występowanie, zapobieganie, leczenie. Klub dla Ciebie. 2006.
Rusiecka-Ziółkowska J, Fleischer M, Staroszczyk J. Właściwości immunologiczne Gram-ujemnych pałeczek Pseudomonas aeruginosa Immunological properties of the Gram-negative bacilli Pseudomonas aeruginosa Word count. 2007:61.
Eron LJ, Judson F, Tucker S, Prawer S, Mills J, Murphy K et al. Interferon therapy for condylomata acuminata. N Engl J Med. 1986;315:1059–64.
Alfred Zejc, Gorczyca M. Współczesne metody projektowania i otrzymywania leków. trzecie. Warszawa: Wydawnictwo Lekarskie PZWL. 2013.
Głobińska A, Kowalski ML. Interferon alfa: Perspektywy zastosowania w leczeniu wirusowych zakażeń dróg oddechowych. Alerg. Astma Immunol. 2013;18:97–103.
Domagalski K, Tretyn A, Pawłowska M, Szczepanek J, Halota W. Action of type III IFNs and their roles in immune responses. Postepy Hig. Med. Dosw. 2010;64:522–33.
Buczko W. Farmakologia i toksykologia. 2012.
Jakóbisiak M. Immunologia. 2000.
Tencate V, Sainz B, Cotler SJ, Uprichard SL. Potential treatment options and future research to increase hepatitis C virus treatment response rate. Hepatic Med. Evid. Res. 2010;2:125–45.
Powell DW, Abramson BZ, Balint JA, Belle S, Bloomer JR, Diehl AK et al. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology. 1997;26:2S-10S.
Tine’ F, Magrin S, Craxi’ A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J. Hepatol. 1991;13:192–9.
Thévenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update. J. Viral Hepat. 2008;8:48–62.
Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology. 1994;107:812–7.
Pawłowski T. Rola szlaku kinureninowego w patogenezie objawów zespołu depresyjnego u pacjentów z przewlekłym wirusowym zapaleniem wątroby typu C leczonych pegylowanym interferonem alfa 2a i rybawiryną. 2011.
Jakóbisiak M. Immunologia. 1995.
Juszczyk J. Leczenie chorób wirusowych. 2000.
Carpenter G, Cohen S. Epidermal Growth Factor. Annu. Rev. Biochem. 1979;48:193–216.
Guidi AJ, Abu-Jawdeh G, Tognazzi K, Dvorak HF, Brown LF. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer. 1996;78:454–60.
Bruijn JA, Roos A, de Geus B, de Heer E. Transforming growth factor-beta and the glomerular extracellular matrix in renal pathology. J. Lab. Clin. Med. 1994;123:34–47.
Han ZC, Sensebe L, Abgrall JF, Briere J. Platelet factor 4 inhibits human megakaryocytopoiesis in vitro. Blood. 1990;75:1234–9.
Hoffman R. Regulation of Megakaryocytopoiesis. Blood. 1989;74:1196–212.
Jacobs L, O’Malley J, Freeman A, Ekes R. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science (80-. ). 1981;214:1026–8.
Erickson-Miller CL, Parchment RE, Zhang ZG, Ji H, Dai W, Murphy MJ et al. Purification of human megakaryocyte colony-stimulating factor (Meg-CSF) from urine of aplastic anemia patients. Int. J. Cell Cloning. 1991;9:204–21.
Hart CE, Bailey M, Curtis DA, Osborn S, Raines E, Ross R et al. Purification of PDGF-AB and PDGF-BB from Human Platelet Extracts and Identification of All Three PDGF Dimers in Human Platelets. Biochemistry. 1990;29:166–72.
Gospodarowicz D. Fibroblast growth factor. Crit. Rev. Oncog. 1989;1:1–26.
Clemmons DR, Van Wyk JJ. Factors controlling blood concentration of somatomedin C. Clin. Endocrinol. Metab. 1984;13:113–43.
Gleave ME, Hsieh JT, Wu HC, Hong SJ, Zhau HE, Guthrie PD et al. Epidermal Growth Factor Receptor-mediated Autocrine and Paracrine Stimulation of Human Transitional Cell Carcinoma. Cancer Res. 1993;53:5300–7.
Fisher DA, Lakshmanan J. Metabolism and effects of epidermal growth factor and related growth factors in mammals. Endocr. Rev. 1990;11:418–42.
Graham GJ, Pragnell IB. SCI MIP-1α: A potent stem cell inhibitor with potential roles in development. Dev. Biol. 1992;151:377–81.
Anderson DJ. New roles for PDGF and CNTF in controlling the timing of glial cell differentiation in the optic nerve. Trends Neurosci. 1989;12:83–5.
Okano M, Thiele GM, Gross TG, Davis JR, Purtilo DT. Differential cellular susceptibility to Epstein‐Barr virus infection in a patient with X‐linked lymphoproliferative disease. J. Med. Virol. 1990;32:47–52.
Fujisaki T. Gamma-Interferon for Severe Chronic Active Epstein-Barr Virus. Ann. Intern. Med. 1993;118:474.
Łucka M, Kowalczyk T, Szemraj J, T. S. Rośliny jako alternatywne źródła białek terapeutycznych. Postepy Hig. Med. Dosw. 2015;69:362–73.
Drosik A, Drosik K. Leczenie chorych na przerzutowego raka nerkowokomórkowego — fakty czy logika poparta faktami ? 2010:311–7.
Seferyńska I, Warzocha K. Postęp w leczeniu przewlekłej białaczki szpikowej. Onkol. w Prakt. Klin. 2005;1:40–8.
Derynck R, Goeddel D V., Ullrich A, Bringman TS, Berger WH, Gutterman JU et al. Synthesis of Messenger RNAs for Transforming Growth Factors α and β and the Epidermal Growth Factor Receptor by Human Tumors. Cancer Res. 1987;47:707–12.
Erickson‐Miller CL, Ji H, Parchment RE, Murphy MJ. Megakaryocyte colony‐stimulating factor (Meg‐CSF) is a unique cytokine specific for the megakaryocyte lineage. Br. J. Haematol. 1993;84:197–203.
Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat. Med. 2020;26:450–2.
World Health Organization. Situation updates on June 22, 2020. .
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’’ in COVID-19.’ J. Infect. 2020;80:607–13.
Nile SH, Nile A, Qiu J, Li L, Jia X, Kai G. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020. doi:10.1016/j.cytogfr.2020.05.002.
Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv. 2020:2020.02.10.20021832.
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’’ in COVID-19.’ J. Infect. 2020;80:607–13.
Stockman LJ, Bellamy R, Garner P. SARS: Systematic Review of Treatment Effects. PLoS Med. 2006;3:e343.
Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020. doi:10.1016/j.antiviral.2020.104791.
Fuk-Woo Chan J, Yao Y, Yeung M-L, Deng W, Bao L, Jia L et al. Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. 2015. doi:10.1093/infdis/jiv392.
Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 2020;11:1–14.
Falzarano D, De Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci. Rep. 2013;3:1–6.
Arabi YM, Shalhoub S, Al-Omari A, Mandourah Y, Al-Hameed F, Sindi A et al. Effect of ribavirin and interferon on the outcome of critically ill patients with MERS. Am. J. Respir. Crit. Care Med. 2017.
Hung IFN, Lung KC, Tso EYK, Liu R, Chung TWH, Chu MY et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395:1695–704.
Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: An observational study. Int. J. Infect. Dis. 2014;20:42–6.
Shalhoub S, Farahat F, Al-Jiffri A, Simhairi R, Shamma O, Siddiqi N et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: A retrospective study. J. Antimicrob. Chemother. 2015;70:2129–32.
Frieman M, Yount B, Heise M, Kopecky-Bromberg SA, Palese P, Baric RS. Severe Acute Respiratory Syndrome Coronavirus ORF6 Antagonizes STAT1 Function by Sequestering Nuclear Import Factors on the Rough Endoplasmic Reticulum/Golgi Membrane. J. Virol. 2007;81:9812–24.
Kopecky-Bromberg SA, Martínez-Sobrido L, Frieman M, Baric RA, Palese P. Severe Acute Respiratory Syndrome Coronavirus Open Reading Frame (ORF) 3b, ORF 6, and Nucleocapsid Proteins Function as Interferon Antagonists. J. Virol. 2007;81:548–57.
Lokugamage KG, Hage A, Schindewolf C, Rajsbaum R, Menachery VD. SARS-CoV-2 is sensitive to type I interferon pretreatment. Cold Spring Harbor Laboratory. 2020;21:1–9.
Shen KL, Yang YH. Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue. World J. Pediatr. 2020:1–3.
Thiel V, Weber F. Interferon and cytokine responses to SARS-coronavirus infection. Cytokine Growth Factor Rev. 2008;19:121–32.
Menachery VD, Yount BL, Josset L, Gralinski LE, Scobey T, Agnihothram S et al. Attenuation and Restoration of Severe Acute Respiratory Syndrome Coronavirus Mutant Lacking 2’-O-Methyltransferase Activity. J. Virol. 2014;88:4251–64.
Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China. Clin. Immunol. 2020;214:108393.
Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov. Ther. 2020;14:58–60.
Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci. Trends. 2020;14:69–71.
Downloads
Published
How to Cite
Issue
Section
License
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 576
Number of citations: 0
